HCPLive | The American Journal of Managed Care | Pharmacy Times | OTCGuide.net | Politics | ONCLive | Medgadget | EchoJournal
KevinMD | Medical Smartphones | Medicine and Technology | Mobile Health Computing | Non-Clinical Medical Jobs, Careers, and Opportunities

You may type link codes into the search box above.
Register   |   Login
 
 
   ash
 
Conference 360

This meeting is "the world's pre-eminent gathering of healthcare professionals devoted to understanding, treating, assessing and preventing cardiovascular disease and stroke." You will find a wide range symposiums, poster presentations, and opportunities to network with your colleagues.

Day 1:

JAK2 Inhibitor Improves Quality of Life for Patients with Myelofibrosis 

Bendamustine Plus Rituximab Bests Current Standard of Care for Indolent Lymphoma

Potential Breakthrough Treatment for CML Patients Who Harbor Imatinib-Resistant T315I Mutation

Vitamin D Deficiency Linked to Poorer Outcomes in Diffuse Large B-Cell Lymphoma

Advanced Care Planning Associated with More Practical Coping Skills in Patients with Hematologic Malignancies

Day 2:

Online Case Database Gathers Clinical and Psychosocial Information for Multiple Myeloma Patients

Lenalidomide Demonstrates Effectiveness in Aggressive B-Cell NHL

Phase III Extended Trial Finds Pixantrone Favorable Compared with Commonly Used Chemotherapies in Aggressive NHL

Melphalan Safer than Thalidomide in Bortezomib-Regimen for Elderly Multiple Myeloma Patients

Three Studies Find Romiplostim Safe and Effective in Patients with MDS

Day 3:

Plerixafor Plus G-CSF for CD34+ Cell Mobilization Offers Benefits Compared with Chemotherapy Plus G-CSF

Dabigatran versus Warfarin in VTE

Conventional CHOEP-R Beats Intensified CHOEP-R in Younger Patients with Aggressive B-Cell NHL

Fludarabine plus Alemtuzumab May Improve Outcomes for Patients with Relapsed or Refractory CLL

Long-term Overall Survival Data Positive for Bexxar in Treatment-Naïve Follicular Lymphoma

Lenalidomide Plus Bortezomib and Dexamethasone (RVD) Produces 100% Response in Multiple Myeloma Patients 

Day 4:

Will Nilotinib Supplant Imatinib as First-line Therapy for CML? 

Data Promising for Oral AP24534 in Refractory CML and Other Hematologic Malignancies

PROPEL Study Reinforces Viability of Pralatrexate in Peripheral T-cell Lymphoma; Cost Questioned

Targeted Agent Appears Promising in Inducing Cancer Cell Apoptosis in Chronic Leukemia Model

REVEAL-1 Trial Data Show Voreloxin to be Safe and Effective in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

 

 
Advertisement

 
   
 
   

Intellisphere, LLC l 666 Plainsboro Road, Building 300, Plainsboro, NJ 08536 l P 609-716-7777 l F 609-716-4747
Copyright ©MDNG 2006-2010
Intellisphere, LLC
All Rights Reserved